Half-life extension of a single-chain diabody by fusion to domain B of staphylococcal protein A
Open Access
- 11 January 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Protein Engineering, Design and Selection
- Vol. 25 (2) , 81-88
Abstract
Binding of a therapeutic protein to a long-circulating plasma protein can result in a strongly extended half-life. Among these plasma proteins, albumin and immunoglobulins are of special interest because of their exceptionally long half-life, which is to a great extent determined by recycling through the neonatal Fc receptor (FcRn). Many strategies have been established employing reversible binding to albumin, e.g. using an albumin-binding domain from streptococcal protein G. We show here that the half-life of a recombinant antibody molecule can also be prolonged by fusion to a single immunoglobulin-binding domain (IgBD) from staphylococcal protein A. This domain (domain B, SpAB) is composed of 56 amino acid residues and was fused to the C-terminus of a bispecific single-chain diabody (scDb). The scDb-SpAB fusion protein was produced in HEK293 cells and retained its antigen-binding activity as shown by enzyme-linked immunosorbent assay and flow cytometry. Furthermore, the fusion protein was capable of binding to human and mouse IgG in a pH-dependent manner. In mice, the terminal half-life of the fusion protein was improved from ∼1–2 h of the unmodified scDb to 11.8 h. Although the fusion protein did not reach the long half-life seen for IgG, our results established the applicability of a single bacterial IgBD for half-life extension purposes.Keywords
This publication has 34 references indexed in Scilit:
- Extending Half-life by Indirect Targeting of the Neonatal Fc Receptor (FcRn) Using a Minimal Albumin Binding DomainJournal of Biological Chemistry, 2011
- TNF receptor I on human keratinocytes is a binding partner for staphylococcal protein A resulting in the activation of NF kappa B, AP-1, and downstream gene transcriptionExperimental Dermatology, 2010
- Albinterferon-alfa 2b: a new treatment option for hepatitis CExpert Opinion on Biological Therapy, 2010
- TNFRI is a positive T‐cell costimulatory molecule important for the timing of cytokine responsesImmunology & Cell Biology, 2010
- Engineered protein scaffolds as next-generation antibody therapeuticsCurrent Opinion in Chemical Biology, 2009
- The Major Histocompatibility Complex–related Fc Receptor for IgG (FcRn) Binds Albumin and Prolongs Its LifespanJournal of Experimental Medicine, 2003
- Pharmacokinetics and biodistribution of genetically engineered antibodiesCurrent Opinion in Biotechnology, 2002
- Pharmaceutical Strategies Utilizing Recombinant Human Serum AlbuminPharmaceutical Research, 2002
- Determination of the binding affinity of an anti-CD34 single-chain antibody using a novel, flow cytometry based assayJournal of Immunological Methods, 1997
- Crystal structure of the complex of rat neonatal Fc receptor with FcNature, 1994